Format

Send to

Choose Destination
J Clin Invest. 2019 Sep 3;129(9):3511-3520. doi: 10.1172/JCI129484.

The supply chain of human pancreatic β cell lines.

Author information

1
INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, France.
2
Beta Cell Neogenesis (BENE), Vrije Universiteit Brussel, Brussels, Belgium.

Abstract

Patients with type 1 or type 2 diabetes have an insufficiency in their functional β cell mass. To advance diabetes treatment and to work toward a cure, a better understanding of how to protect the pancreatic β cells against autoimmune or metabolic assaults (e.g., obesity, gestation) will be required. Over the past decades, β cell protection has been extensively investigated in rodents both in vivo and in vitro using isolated islets or rodent β cell lines. Transferring these rodent data to humans has long been challenging, at least partly for technical reasons: primary human islet preparations were scarce and functional human β cell lines were lacking. In 2011, we described a robust protocol of targeted oncogenesis in human fetal pancreas and produced the first functional human β cell line, and in subsequent years additional lines with specific traits. These cell lines are currently used by more than 150 academic and industrial laboratories worldwide. In this Review, we first explain how we developed the human β cell lines and why we think we succeeded where others, despite major efforts, did not. Next, we discuss the use of such functional human β cell lines and share some perspectives on their use to advance diabetes research.

PMID:
31478912
PMCID:
PMC6715382
[Available on 2020-09-03]
DOI:
10.1172/JCI129484
Free full text

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation
Loading ...
Support Center